Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subdermal re-injection: a method to increase surgical detection of the sentinel node in breast cancer without increasing the false-negative rate.
Bajén MT, Benítez A, Mora J, Ricart Y, Ferran N, Guirao S, Carrera D, Gil M, Pla MJ, Gumá A, Palacin JA, Martin-Comin J. Bajén MT, et al. Among authors: guma a. Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):338-43. doi: 10.1007/s00259-005-1931-8. Epub 2005 Nov 24. Eur J Nucl Med Mol Imaging. 2006. PMID: 16307292
Sentinel node localization in patients with non-palpable breast cancer.
Fernandez A, Escobedo A, Benito E, Azpeitia D, Guma A, Prieto L, Moreno A, Martin-Comin J. Fernandez A, et al. Among authors: guma a. Nucl Med Commun. 2002 Dec;23(12):1165-9. doi: 10.1097/00006231-200212000-00003. Nucl Med Commun. 2002. PMID: 12464780 Clinical Trial.
Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective study.
Garcia-Tejedor A, Falo C, Quetglas C, Soler T, Marqueta B, Ortega R, Gil-Gil M, Pernas S, Fernandez-Montolí E, Pla MJ, Guma A, Bajen M, Benitez A, Eraso A, Campos M, Petit A, Ponce J. Garcia-Tejedor A, et al. Among authors: guma a. Int J Surg. 2017 Mar;39:141-147. doi: 10.1016/j.ijsu.2017.01.106. Epub 2017 Jan 30. Int J Surg. 2017. PMID: 28153783 Free article.
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Garcia-Tejedor A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, Perez-Montero H, Fernandez-Montolí E, Stradella A, Recalde S, Soler T, Petit A, Bajen MT, Benitez A, Guma A, Campos M, Pla MJ, Martinez E, Laplana M, Pernas S, Perez-Sildekova D, Catala I, Ponce J, Falo C. Garcia-Tejedor A, et al. Among authors: guma a. Breast Cancer Res Treat. 2021 Feb;185(3):657-666. doi: 10.1007/s10549-020-05970-2. Epub 2020 Oct 17. Breast Cancer Res Treat. 2021. PMID: 33068198
Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.
Fernandez-Gonzalez S, Falo C, Pla MJ, Verdaguer P, Nuñez D, Guma A, Soler T, Vethencourt A, Vázquez S, Fernandez-Montoli ME, Campos M, Pernas S, Gil M, Ponce J, Garcia-Tejedor A. Fernandez-Gonzalez S, et al. Among authors: guma a. Breast J. 2020 May;26(5):888-896. doi: 10.1111/tbj.13763. Epub 2020 Feb 13. Breast J. 2020. PMID: 32052521
The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
Ortega Expósito C, Falo C, Pernas S, Pérez Carton S, Gil Gil M, Ortega R, Pérez Montero H, Stradella A, Martinez E, Laplana M, Salinas S, Luzardo A, Soler T, Fernández Montoli ME, Azcarate J, Guma A, Petit A, Benitez A, Bajen M, Reyes Junca JG, Campos M, Ruiz R, Ponce J, Pla MJ, García Tejedor A. Ortega Expósito C, et al. Among authors: guma a. Breast Cancer Res Treat. 2021 Aug;189(1):111-120. doi: 10.1007/s10549-021-06274-9. Epub 2021 Jun 4. Breast Cancer Res Treat. 2021. PMID: 34089119
Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsy.
Salinas-Huertas S, Luzardo-González A, Vázquez-Gallego S, Pernas S, Falo C, Pla MJ, Gil-Gil M, Beranuy-Rodriguez M, Pérez-Montero H, Gomila-Sancho M, Manent-Molina N, Arencibia-Domínguez A, Gonzalez-Pineda B, Tormo-Collado F, Ortí-Asencio M, Terra J, Martinez-Perez E, Mestre-Jane A, Campos-Varela I, Jaraba-Armas M, Benítez-Segura A, Campos-Delgado M, Fernández-Montolí ME, Valverde-Alcántara Y, Rodríguez A, Campos G, Guma A, Ponce-Sebastià J, Planas-Balagué R, Catasús-Clavé M, García-Tejedor A. Salinas-Huertas S, et al. Among authors: guma a. Breast Dis. 2022;41(1):97-108. doi: 10.3233/BD-210043. Breast Dis. 2022. PMID: 34542055
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR. Pernas S, et al. Among authors: guma a. Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8. Breast Cancer Res Treat. 2012. PMID: 22772380 Clinical Trial.
86 results